secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001171843-23-005225
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose Q2 net loss $14.1M; TUS/VEN doublet 50% CRc; Hanmi commits up to $7M
---------------------------------------------------------------------------

- TUS/VEN doublet: 50% CRc (5/10 evaluable); 44% CRc in prior-venetoclax failures (4/9); 43% in FLT3-WT (3/7).
- Hanmi Pharma commits up to $7M or 19.99% ownership in two tranches; first $3M by Aug-end conditional on TSX listing.
- Q2 net loss $14.1M vs $10.6M prior year; cash $23.3M at June 30, expected to fund operations through March 2024.
- FDA End of Phase 1 meeting completed; monotherapy RP2D of 80 mg daily confirmed; accelerated path remains open.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184323005225/0001171843-23-005225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184323005225/f8k_081023.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-005225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer